Abstract
The epidermal growth factor receptor is homologous to the oncogene erb-beta and is the receptor for a class of tumour growth factors (TGF-alpha). The clinical correlations with its expression were studied in 77 non-small cell lung cancers (NSCLC). They were stained for epidermal growth factor receptor (EGFr) by means of an indirect immunoperoxidase technique using a monoclonal antibody against the receptor. Normal lung tissue and normal bronchus were stained for comparison. Cancer tissue showed significantly increased staining compared to normal lung (P less than 0.05). Staining for EGFr in 40 squamous carcinomas was significantly stronger than in 37 specimens of other types of NSCLC (P less than 0.05), and staining in stage three NSCLC was stronger than in stage 1 and 2 (P less than 0.05). These results suggest that the presence of a high intensity of staining for EGF receptor is associated with spread of human non-small cell lung cancer and this receptor may be a suitable target for therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Veale, D., Ashcroft, T., Marsh, C. et al. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55, 513–516 (1987). https://doi.org/10.1038/bjc.1987.104
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.104
This article is cited by
-
Coupled folding-upon-binding of human tumor suppressor MIG6 to lung cancer EGFR kinase domain and molecular trimming/stapling of MIG6-derived β-hairpins to target the coupling event
European Biophysics Journal (2023)
-
Kinase drug discovery 20 years after imatinib: progress and future directions
Nature Reviews Drug Discovery (2021)
-
Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients
Journal of Cancer Research and Clinical Oncology (2021)
-
Overview of current targeted therapy in gallbladder cancer
Signal Transduction and Targeted Therapy (2020)
-
MultiDCoX: Multi-factor analysis of differential co-expression
BMC Bioinformatics (2017)